Press Releases | EyePoint Pharmaceuticals

Year

pSivida Corp. Reports Fiscal 2017 First Quarter Results and Provides Update on Corporate Objectives & Milestone Timeline Nov 07, 2016 New Leadership Focused on Increasing Commercial Potential of Proven Durasert ™ Sustained Release Platform Company Continues Focus on MAA and NDA Filings for Uveitis Product in 2017 Conference Call and Webcast Today, November 7 , at 4:30 p.m. ET WATERTOWN, Mass. , Nov. Read more
pSivida Corp. Announces First Quarter Fiscal Year 2017 Financial Results Release Date and Conference Call Information Oct 31, 2016 WATERTOWN, Mass. , Oct. 31, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for treating eye diseases, today announced its financial results for the first quarter of fiscal year 2017 will be released Read more
Phase 3 trial of Medidur™ in Posterior Segment Uveitis Meets Enrollment Target Oct 04, 2016 Study is the Second of Two Ongoing Phase 3 Trials in Support Of Product Registration in the US EU Filing Remains on Track for 1Q2017 Filing WATERTOWN, Mass. , Oct. 04, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug technologies Read more
pSivida Corp. Strengthens Board of Directors With Leading Ophthalmologist Sep 27, 2016 WATERTOWN, Mass. , Sept. 27, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced the appointment of Jay S. Duker , M.D, to the Company's Board of Directors. Dr. Read more
pSivida to Present at the Ladenburg Thalmann Annual Healthcare Conference Sep 22, 2016 WATERTOWN, Mass. , Sept. 22, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced today that Nancy Lurker , the Company's newly-appointed President and Chief Executive Officer, Read more
pSivida Reports Inducement Awards to New President and Chief Executive Officer Sep 20, 2016 WATERTOWN, Mass. , Sept. 20, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, today reported the grant of inducement awards to its new President and Chief Executive Officer, Nancy Read more
pSivida Implements Leadership Change -- Nancy Lurker Named as President and CEO Sep 15, 2016 WATERTOWN, Mass. , Sept. 15, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced that its Board of Directors has appointed Nancy Lurker as its President and Chief Executive Read more
pSivida Corp. Provides Company Update and Reports Fourth Quarter and FY 2016 Results Sep 12, 2016 WATERTOWN, Mass. , Sept. 12, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today provided a Company update and announced financial results for its fourth quarter and fiscal year Read more
pSivida Corp. Announces Fourth Quarter and Fiscal Year 2016 Financial Results Release Date and Conference Call Information Sep 01, 2016 WATERTOWN, Mass. , Sept. 01, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for treating eye diseases, today announced its financial results for the fourth quarter and fiscal year 2016 will be Read more
pSivida Announces 13 New Patents Issued or Allowed Aug 29, 2016 U.S. and foreign patents for bioerodible Medidur™, new smaller needle Medidur injector and Tethadur™ Read more
Topline Results from First Phase 3 Trial of pSivida's Medidur™ Presented at ASRS Annual Meeting Aug 15, 2016 WATERTOWN, Mass. , Aug. 15, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced that Dr. Glenn J. Jaffe , Robert Machemer Professor of Ophthalmology at Duke University School of Read more
Primary Endpoint Met in pSivida's Utilization Study of New Medidur™ Inserter with Smaller Diameter Needle Aug 09, 2016 Results to Form Part of Planned Applications for Marketing Approvals in EU and US Read more
pSivida Names Dario Paggiarino, M.D. as Chief Medical Officer Aug 03, 2016 Industry Veteran Brings Over 25 Years of Pharmaceutical and Drug Development Experience Read more
pSivida Corp and Hospital for Special Surgery Innovation Center Announce Opening of IND for Sustained-Release Implant for Severe Knee Osteoarthritis Aug 01, 2016 WATERTOWN, Mass. and NEW YORK , Aug. 01, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for eye diseases, and Hospital for Special Surgery (HSS), America's leading specialty hospital devoted to orthopedics and Read more
pSivida's Medidur™ Maintains Same High Statistical Significance in Primary Endpoint through 12 Months in First Phase 3 Trial (p Less Than 0.00000001) Jul 27, 2016 Incremental Risk of Elevated IOP Relative to Control Decreases Through Last Follow-up Visit Read more
Data Shows pSivida's Tethadur™ Provides Prolonged, Sustained Release of Avastin® With High Drug Efficacy Jul 20, 2016 Data Presented at 2016 Annual Meeting & Exposition of the Controlled Release Society Read more
pSivida Corp. Announces Plan to Consolidate all Research and Development in Current U.S. Facility Jul 15, 2016 Plan to Facilitate Product Development and Reduce Operating Expenses Read more
Investigator-Sponsored Phase 2 Study Results Show pSivida's Medidur® Fully Controlled Uveitis for Two Years with No Recurrence of Disease While Visual Acuity Continued to Improve Jul 14, 2016 Study Results Showing No Recurrence of Disease and Statistically Significant Improvement in Visual Acuity to be Published in Ophthalmology Read more
pSivida Announces Poster and Oral Presentation on Controlled Release of Avastin® from Tethadur™ Biodegradable Matrix at the 2016 Controlled Release Society Annual Meeting Jul 08, 2016 WATERTOWN, Mass. , July 08, 2016 (GLOBE NEWSWIRE) -- pSivida Corp (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced that pSivida's Dr. Catherine Kelly will present a poster and oral presentation on "The Controlled Read more
pSivida Announces Successful Completion of Two Preclinical Studies of Durasert™ Sustained-Release Insert Delivering Repurposed Cancer Drug to Treat Wet AMD Jul 05, 2016 Promising Results for Potential Sustained Treatment of Wet AMD Using a TKI Read more

pSivida Corp. Reports Fiscal 2017 First Quarter Results and Provides Update on Corporate Objectives & Milestone Timeline

Nov 07, 2016

New Leadership Focused on Increasing Commercial Potential of Proven Durasert ™ Sustained Release Platform Company Continues Focus on MAA and NDA Filings for Uveitis Product in 2017 Conference Call and Webcast Today, November 7 , at 4:30 p.m. ET WATERTOWN, Mass. , Nov.

pSivida Corp. Announces First Quarter Fiscal Year 2017 Financial Results Release Date and Conference Call Information

Oct 31, 2016

WATERTOWN, Mass. , Oct. 31, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for treating eye diseases, today announced its financial results for the first quarter of fiscal year 2017 will be released

Phase 3 trial of Medidur™ in Posterior Segment Uveitis Meets Enrollment Target

Oct 04, 2016

Study is the Second of Two Ongoing Phase 3 Trials in Support Of Product Registration in the US EU Filing Remains on Track for 1Q2017 Filing WATERTOWN, Mass. , Oct. 04, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug technologies

pSivida Corp. Strengthens Board of Directors With Leading Ophthalmologist

Sep 27, 2016

WATERTOWN, Mass. , Sept. 27, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced the appointment of Jay S. Duker , M.D, to the Company's Board of Directors. Dr.

pSivida to Present at the Ladenburg Thalmann Annual Healthcare Conference

Sep 22, 2016

WATERTOWN, Mass. , Sept. 22, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced today that Nancy Lurker , the Company's newly-appointed President and Chief Executive Officer,

pSivida Reports Inducement Awards to New President and Chief Executive Officer

Sep 20, 2016

WATERTOWN, Mass. , Sept. 20, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, today reported the grant of inducement awards to its new President and Chief Executive Officer, Nancy

pSivida Implements Leadership Change -- Nancy Lurker Named as President and CEO

Sep 15, 2016

WATERTOWN, Mass. , Sept. 15, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced that its Board of Directors has appointed Nancy Lurker as its President and Chief Executive

pSivida Corp. Provides Company Update and Reports Fourth Quarter and FY 2016 Results

Sep 12, 2016

WATERTOWN, Mass. , Sept. 12, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today provided a Company update and announced financial results for its fourth quarter and fiscal year

pSivida Corp. Announces Fourth Quarter and Fiscal Year 2016 Financial Results Release Date and Conference Call Information

Sep 01, 2016

WATERTOWN, Mass. , Sept. 01, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for treating eye diseases, today announced its financial results for the fourth quarter and fiscal year 2016 will be

pSivida Announces 13 New Patents Issued or Allowed

Aug 29, 2016

U.S. and foreign patents for bioerodible Medidur™, new smaller needle Medidur injector and Tethadur™

Topline Results from First Phase 3 Trial of pSivida's Medidur™ Presented at ASRS Annual Meeting

Aug 15, 2016

WATERTOWN, Mass. , Aug. 15, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced that Dr. Glenn J. Jaffe , Robert Machemer Professor of Ophthalmology at Duke University School of

Primary Endpoint Met in pSivida's Utilization Study of New Medidur™ Inserter with Smaller Diameter Needle

Aug 09, 2016

Results to Form Part of Planned Applications for Marketing Approvals in EU and US

pSivida Names Dario Paggiarino, M.D. as Chief Medical Officer

Aug 03, 2016

Industry Veteran Brings Over 25 Years of Pharmaceutical and Drug Development Experience

pSivida Corp and Hospital for Special Surgery Innovation Center Announce Opening of IND for Sustained-Release Implant for Severe Knee Osteoarthritis

Aug 01, 2016

WATERTOWN, Mass. and NEW YORK , Aug. 01, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for eye diseases, and Hospital for Special Surgery (HSS), America's leading specialty hospital devoted to orthopedics and

pSivida's Medidur™ Maintains Same High Statistical Significance in Primary Endpoint through 12 Months in First Phase 3 Trial (p Less Than 0.00000001)

Jul 27, 2016

Incremental Risk of Elevated IOP Relative to Control Decreases Through Last Follow-up Visit

Data Shows pSivida's Tethadur™ Provides Prolonged, Sustained Release of Avastin® With High Drug Efficacy

Jul 20, 2016

Data Presented at 2016 Annual Meeting & Exposition of the Controlled Release Society

pSivida Corp. Announces Plan to Consolidate all Research and Development in Current U.S. Facility

Jul 15, 2016

Plan to Facilitate Product Development and Reduce Operating Expenses

Investigator-Sponsored Phase 2 Study Results Show pSivida's Medidur® Fully Controlled Uveitis for Two Years with No Recurrence of Disease While Visual Acuity Continued to Improve

Jul 14, 2016

Study Results Showing No Recurrence of Disease and Statistically Significant Improvement in Visual Acuity to be Published in Ophthalmology

pSivida Announces Poster and Oral Presentation on Controlled Release of Avastin® from Tethadur™ Biodegradable Matrix at the 2016 Controlled Release Society Annual Meeting

Jul 08, 2016

WATERTOWN, Mass. , July 08, 2016 (GLOBE NEWSWIRE) -- pSivida Corp (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced that pSivida's Dr. Catherine Kelly will present a poster and oral presentation on "The Controlled

pSivida Announces Successful Completion of Two Preclinical Studies of Durasert™ Sustained-Release Insert Delivering Repurposed Cancer Drug to Treat Wet AMD

Jul 05, 2016

Promising Results for Potential Sustained Treatment of Wet AMD Using a TKI

First page
Previous page
…
Page 11
Page 12
Page 13
Page 14
Current page 15
Page 16
Page 17
Page 18
Page 19
…
Next page
Last page

Displaying 281 - 300 of 545

News releases are posted on the Company's website as soon as possible after the release over the news wire. You should view the Financial Information section and most recent SEC Filings in the Investors section to receive the most current information made available by EyePoint Pharmaceuticals, Inc.